(Q37828640)

24 August 2017

1 reference

title

Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies (English)

1 reference

24 August 2017

hepatocellular carcinoma

1 reference

R Lord

1

1 reference

PubMed ID

21235699

24 August 2017

A Suddle

series ordinal

2

1 reference

PubMed ID

21235699

24 August 2017

P J Ross

series ordinal

3

1 reference

24 August 2017

1 February 2011

1 reference

International Journal of Clinical Practice

24 August 2017

1 reference

24 August 2017

65

1 reference

24 August 2017

2

1 reference

24 August 2017

182-188

1 reference

24 August 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Systemic therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Clinical trials in primary hepatocellular carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Anticancer drug targets: growth factors and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Increased MAPK expression and activity in primary human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

Strategies for the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02545.X

10.1111/J.1742-1241.2010.02545.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21235699